Oxra-S 5/50 Mg (Dapagliflozin/Sitagliptin)

Description

Introduction

Oxra-S 5/50 Mg is an oral tablet containing dapagliflozin 5 mg and sitagliptin 50 mg. The product is presented for type 2 diabetes. Its ingredients act in different ways to help lower blood glucose. Whether this combination is appropriate depends on a person’s health conditions, kidney function and other medicines.

Blood glucose medicines form one part of diabetes care, which may also include food choices, physical activity and regular monitoring. A healthcare professional can provide guidance about this particular product.

What Is It?

Oxra-S 5/50 Mg combines two types of glucose-lowering medicine in one tablet. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor.

The tablet is presented for managing type 2 diabetes. It is not a treatment for type 1 diabetes or diabetic ketoacidosis. Ask a pharmacist if information about inactive ingredients or whether the tablet can be split or crushed is needed.

How Does It Work?

Dapagliflozin acts in the kidneys. It reduces the amount of filtered glucose returned to the bloodstream, allowing more glucose to leave the body in urine. Increased urination can also contribute to fluid loss.

Sitagliptin increases the activity of natural hormones called incretins. When blood glucose is high, these hormones help the pancreas release insulin and reduce glucose production by the liver. The two ingredients therefore lower blood glucose through different mechanisms.

Common Uses

Dapagliflozin and sitagliptin are used to help lower blood glucose in people with type 2 diabetes. A clinician may consider a person’s blood glucose results, kidney function, other health conditions and current medicines when assessing treatment.

Dapagliflozin alone has uses relating to heart failure and chronic kidney disease in some settings. Those uses should not be assumed to apply to this combination tablet. Ask a healthcare professional for guidance about its intended use.

Available Strengths

This family is available in 50 mg, 100 mg.

Key Features

• Each tablet is presented as containing dapagliflozin 5 mg and sitagliptin 50 mg.
• Dapagliflozin increases glucose excretion through the urine.
• Sitagliptin acts through the body’s incretin hormones.
• Both active ingredients are contained in one oral tablet.
• The product is presented for type 2 diabetes management.

Benefits

• The ingredients have different, established actions that can help lower blood glucose.
• One tablet contains both ingredients at the stated strengths.
• Changes in glucose control can be assessed through follow-up tests, including HbA1c.

The effect of treatment varies between people. A healthcare professional can explain how glucose results will be monitored and whether the medicine is meeting an individual treatment goal.

Possible Side Effects

• Dapagliflozin may cause more frequent urination, genital fungal infections or urinary tract infections.
• Fluid loss may cause dehydration, dizziness or low blood pressure.
• Sitagliptin may cause headache, nausea, diarrhoea or symptoms affecting the nose and throat.
• Low blood glucose is more likely when these ingredients are used with insulin or a sulfonylurea.
• Serious problems associated with the ingredients include diabetic ketoacidosis, pancreatitis and severe allergic reactions.

Vomiting, abdominal pain, unusual tiredness or difficulty breathing can be signs of ketoacidosis and need urgent medical assessment. Severe, persistent abdominal pain may indicate pancreatitis. These are not complete lists of possible side effects.

Precautions

• Kidney function can affect treatment decisions. A clinician may review kidney test results before and during treatment.
• Discuss any history of pancreatitis, heart failure, low blood pressure, ketoacidosis, or recurrent urinary or genital infections with a healthcare professional.
• Tell a clinician if you are pregnant, planning pregnancy or breastfeeding. Ask for product-specific guidance.
• Seek medical advice for symptoms of a urinary infection, dehydration, an allergic reaction or a severe skin reaction.

Additional Precautions

• Illness, reduced food or fluid intake, fasting and surgery can affect risks associated with dapagliflozin. Ask the treating team for guidance in these situations.
• A ketogenic diet or substantial alcohol intake can increase concern about ketoacidosis and should be discussed with a clinician.
• Infection and other acute illnesses can change blood glucose. Follow the monitoring plan provided by the diabetes care team.
• Tell healthcare professionals about all medicines being taken before a procedure or when discussing test results.

Storage Instructions

• Keep the tablets in their original packaging and out of the reach of children.
• Protect them from excess heat and moisture.
• Check the package label or ask a pharmacist for this product’s exact storage conditions and expiry date.
• Ask a pharmacist how to dispose of unwanted or expired tablets.

How to Take

• Follow the directions supplied by the prescribing healthcare professional and with the product.
• Ask a pharmacist to confirm how to take the tablet and whether it can be split or crushed.
• For a missed dose or an accidental extra dose, seek product-specific advice. Do not take a double dose to make up for a missed one.
• Attend recommended reviews of blood glucose, HbA1c and kidney function.

Drug Interactions

• Insulin and sulfonylureas can increase the risk of low blood glucose when used with glucose-lowering treatment.
• Diuretics can add to fluid loss associated with dapagliflozin and may increase the risk of dehydration or low blood pressure.
• Other medicines may affect kidney function or the monitoring needed during treatment.
• Give a clinician or pharmacist a complete list of prescription medicines, over-the-counter products and supplements before starting or changing treatment.

Why Choose This Product?

• It contains dapagliflozin and sitagliptin together in one oral tablet.
• The ingredients act through different mechanisms to help lower blood glucose in type 2 diabetes.
• The stated strengths allow a clinician to assess the product against a person’s treatment plan and kidney function.

Frequently Asked Questions (FAQs)

What does Oxra-S 5/50 Mg contain?

Each tablet is presented as containing dapagliflozin 5 mg and sitagliptin 50 mg. A pharmacist can check the packaging for inactive ingredients.

What is it used for?

It is presented for blood glucose management in type 2 diabetes. A clinician can confirm its place in an individual treatment plan.

Does it treat type 1 diabetes?

No. These ingredients are not used to treat type 1 diabetes.

Does it treat diabetic ketoacidosis?

No. Diabetic ketoacidosis requires urgent medical assessment and treatment.

How do its ingredients differ?

Dapagliflozin increases glucose loss through urine. Sitagliptin acts through incretin hormones to help regulate blood glucose.

Can it cause low blood glucose?

The risk may rise when it is used with insulin or a sulfonylurea. A clinician can explain what to watch for.

Why might kidney tests be needed?

Kidney function affects treatment decisions and monitoring for these ingredients.

What symptoms need urgent attention?

Persistent abdominal pain, vomiting, breathing difficulty or signs of a severe allergic reaction need urgent medical assessment.

How should the tablets be stored?

Keep them in their original packaging, away from excess heat and moisture, and out of children’s reach. Check the package for exact conditions.

Can this medicine replace other parts of diabetes care?

It is one part of a broader care plan. A healthcare professional can advise on food, activity and blood glucose monitoring.

Related Products

• Oxra-S 5/50 Mg (Dapagliflozin/Sitagliptin)
• Oxra-S 5/100 Mg (Dapagliflozin/Sitagliptin)
• Repaglinide 0.5 mg Australia
• Acarbose 50 mg Australia
• Voglibose 0.3 mg Australia
• Glimepiride 4 mg Australia